Drugs

, Volume 74, Issue 3, pp 297–311

T-Cell Trafficking and Anti-Adhesion Strategies in Inflammatory Bowel Disease: Current and Future Prospects

Authors

  • Mahmoud H. Mosli
    • Department of MedicineUniversity of Western Ontario
    • Department of MedicineKing Abdulaziz University
    • Robarts Clinical Trials Inc, Robarts Research InstituteUniversity of Western Ontario
  • Jesus Rivera-Nieves
    • Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease CenterUniversity of California
    • Department of MedicineUniversity of Western Ontario
    • Robarts Clinical Trials Inc, Robarts Research InstituteUniversity of Western Ontario
Review Article

DOI: 10.1007/s40265-013-0176-2

Cite this article as:
Mosli, M.H., Rivera-Nieves, J. & Feagan, B.G. Drugs (2014) 74: 297. doi:10.1007/s40265-013-0176-2

Abstract

The medical management of idiopathic inflammatory bowel disease (IBD) has historically been based upon the use of broad-spectrum anti-inflammatory drugs such as corticosteroids and thiopurines. Recently, the identification of novel mechanisms central to the pathophysiology of IBD has provided more specific targets, including inhibition of leukocyte trafficking to the gut. In this article, we discuss the molecular biology of intestinal leukocyte trafficking and review the emerging therapies that target this process, including vedolizumab, natalizumab, etrolizumab, PF-547659, alicaforsen, efalizumab, and emerging members of this class.

Copyright information

© Springer International Publishing Switzerland 2014